Cargando…

Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?

Drug resistance is a fundamental problem in the treatment of most common human cancers. Our understanding of the cellular mechanisms underlying death and survival has allowed the development of rational approaches to overcoming drug resistance. The mitogen activated protein kinase family of protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Makin, Guy, Dive, Caroline
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138679/
https://www.ncbi.nlm.nih.gov/pubmed/11305949
http://dx.doi.org/10.1186/bcr289
_version_ 1782120472232591360
author Makin, Guy
Dive, Caroline
author_facet Makin, Guy
Dive, Caroline
author_sort Makin, Guy
collection PubMed
description Drug resistance is a fundamental problem in the treatment of most common human cancers. Our understanding of the cellular mechanisms underlying death and survival has allowed the development of rational approaches to overcoming drug resistance. The mitogen activated protein kinase family of protein serine/threonine kinases has been implicated in this complex web of signalling, with some members acting to enhance death and other members to prevent it. A recent publication by MacKeigan et al is the first to demonstrate an enhancement of drug-induced cell death by simultaneous blockade of MEK-mediated survival signalling, and offers the potential for targeted adjuvant therapy as a means of overcoming drug resistance.
format Text
id pubmed-138679
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1386792003-02-27 Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Makin, Guy Dive, Caroline Breast Cancer Res Commentary Drug resistance is a fundamental problem in the treatment of most common human cancers. Our understanding of the cellular mechanisms underlying death and survival has allowed the development of rational approaches to overcoming drug resistance. The mitogen activated protein kinase family of protein serine/threonine kinases has been implicated in this complex web of signalling, with some members acting to enhance death and other members to prevent it. A recent publication by MacKeigan et al is the first to demonstrate an enhancement of drug-induced cell death by simultaneous blockade of MEK-mediated survival signalling, and offers the potential for targeted adjuvant therapy as a means of overcoming drug resistance. BioMed Central 2001 2001-03-28 /pmc/articles/PMC138679/ /pubmed/11305949 http://dx.doi.org/10.1186/bcr289 Text en Copyright © 2001 BioMed Central Ltd
spellingShingle Commentary
Makin, Guy
Dive, Caroline
Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
title Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
title_full Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
title_fullStr Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
title_full_unstemmed Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
title_short Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
title_sort modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138679/
https://www.ncbi.nlm.nih.gov/pubmed/11305949
http://dx.doi.org/10.1186/bcr289
work_keys_str_mv AT makinguy modulatingsensitivitytodruginducedapoptosisthefutureforchemotherapy
AT divecaroline modulatingsensitivitytodruginducedapoptosisthefutureforchemotherapy